MedTrace Logo

Synaptic Loss in Multiple System Atrophy

NCT05121012 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2026-02-10

No results posted yet for this study

Summary

In this study the investigators would like to investigate the degree of damage of the synapses, an important part of the neurons vital for the communications between neurons, in Multiple System Atrophy (MSA), and pathology related to abnormal accumulation of a protein named tau, in Progressive Supranuclear Palsy (PSP).

Conditions

Interventions

OTHER

Study procedures for MSA patients

The group of MSA patients will undergo a collection of demographic data, a neurological examination with administration of clinical scales relevant for MSA, and a collection of venous blood sample for routine and biomarker analyses. Participants will undergo one PET scan with the tracer \[11C\]UCB-J, and one PET scan with the tracer \[18F\]FDG. All participants will also undergo one MRI scan. Participants will also undergo one lumbar puncture (optional). All procedures will be performed at baseline and after one-year follow-up. A subgroup of patients with MSA will also undergo, at one time point only, one PET scan with the tracer \[18F\]APN107.

OTHER

Study procedures for PSP patients

The group of PSP patients will undergo a collection of demographic data, a neurological examination with administration of clinical scales relevant for PSP, and a collection of venous blood sample for routine and biomarker analyses. Participants will undergo one PET scan with the tracer \[18F\]APN107 and one MRI scan. All procedures will be performed at baseline and after one-year follow-up.

Sponsors & Collaborators

  • University of Exeter

    lead OTHER

Principal Investigators

  • Marios Politis, MD MSc PhD · University of Exeter

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05121012 on ClinicalTrials.gov